NDUFC1 and sarcopenia: In this study, the drug analysis showed that metformin is a potential therapeutic agent on sarcopenia via binding to NDUFC1, which may have significant implications for possible therapeutic interventions on sarcopenia, however, the precise mechanism by which metformin act remains further research.